Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (November 2022)

40 slides from Zynerba Pharmaceuticals's investor presentation, Nov 15, 2022

  1. Slide 1: Next-Generation Transdermal Cannabinoid Therapeutics

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQZYNE Advancing Science.Improving Connections.Next-Generation Transdermal Cannabinoid TherapeuticsNovember 2022

  2. Slide 2: Forward-Looking Statements

    Forward-Looking StatementsThe statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other things relate to the future operations, opportunities or financial performance of Zynerba pha

  3. Slide 3: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  4. Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company

    An Orphan-Focused Neuropsychiatric, Biopharmaceutical CompanyZynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation-enhancedPatent-protected through 2040Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical program ongoingTw

  5. Slide 5: Benefits of Our Approach to Cannabidiol

    Benefits of Our Approach to Cannabidiol Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC –not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURINGPHARMACEUTICALDISPENSARY Ease o

  6. Slide 6: Clinical Development Programs

    Clinical Development Programs Fragile X SyndromeFXS 22q Deletion Syndrome22q Autism Spectrum DisorderASD

  7. Slide 7: Overlap of Symptoms Across Conditions

    Overlap of Symptoms Across ConditionsZynerba Pharmaceuticals | Advancing Science. Improving Connections. 7 AnxietySeeks IsolationSocial AvoidanceLack of InteractionAttention DeficitsIrritability FXS22qASDNovember 2022

  8. Slide 8: Focused Clinical Pipeline

    Fragile X Syndrome (FXS)Focused Clinical Pipeline Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 PreclinicalPhase 1Phase 2PivotalMarket 22q Deletion Syndrome (22q) Autism Spectrum Disorder (ASD) Regulatory FilingU.S. Orphan Drug and Fast Track designations; EU Orphan Drug desi

  9. Slide 9: Well-Tolerated Safety Profile

    •Zygel safety database across all clinical studies includes data from over 900 volunteers and patients•Majority of treatment-emergent AEs (TEAE) were mild or moderate •Most common Zygel-related TEAE are application site events, the majority of which were mild and transient •No clinically significant

  10. Slide 10: Fragile X Syndrome

    Fragile X Syndrome

  11. Slide 11: What is Fragile X Syndrome (FXS)

    ~78K U.S. PATIENTSWhat is Fragile X Syndrome (FXS)Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 11 •Leading known cause of inherited intellectual disability and autism spectrum disorder•Mutation of the FMR1gene causes endocannabinoid system (ECS) dysregulation•Easily identified

  12. Slide 12: Poised for Success in FXS

    Poised for Success in FXSZynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylation Lessons

  13. Slide 13: Role of FMR1 Methylation in FXS

    Role of FMR1Methylation in FXSZynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 •FMR1gene codes for production of FMRP* which is vital to synapse development•Methylation of the FMR1gene plays a role in determining gene function•When methylation of the FMR1gene silences the gene,

  14. Slide 14: CONNECT-FX Trial Key Learning: Complete Methylation of FMR1 Gene

    CONNECT-FXTrialKey Learning: Results with complete methylation of FMR1 geneConsistent Improvements Observed with Zygel vs. Placebo in Patients with Complete MethylationZynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CHANGE CLINICIAN

  15. Slide 15: Change in ABC-CFXS Social Avoidance

    Change in ABC-CFXSSocial Avoidance Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 Clinically Meaningful ChangeaAchieved and Maintained in Patients with Complete Methylation of FMR1Geneb 01020 3040506070 8090100012345678910111213141516 Cumulative Percentage of Patients Month Z

  16. Slide 16: Design Optimized from CONNECT-FX Trial

    Design Optimized from CONNECT-FX TrialZynerba Pharmaceuticals | Advancing Science. Improving Connections. 16 More patient and family friendlyExtending trial to 18-weeksIncreased dosing option for individuals >50 kgSuccessful completion of Phase 3 pivotal trial expected to satisfy requirements for an

  17. Slide 17: Confirmatory Pivotal Trial Design

    Confirmatory Pivotal Trial DesignZynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 Double-Blind, Placebo-Controlled Study: Initiated 18 weeks 3 to 17 years oldModerate-to-Severe FXS Zygel (n~100; 80*)250 mg daily (≤30kg)500 mg daily (>30kg)750 mg daily (>50kg)(weight-based dose)

  18. Slide 18: Trial Objectives

    Trial ObjectivesZynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1gene •Change from baseline to end of treatment in:•ABC-CFXS Irritability

  19. Slide 19: Next Steps in FXS

    Next Steps in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 Continued RECONNECTpivotal trial enrollmentTopline results expected in 2H 2023November 2022

  20. Slide 20: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q)Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org ..Eliza, living with 22q11.2 deletion syndrome

  21. Slide 21: What is 22q11.2 Deletion Syndrome (22q)?

    What is 22q11.2 Deletion Syndrome (22q)?Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 21 •Rare disorder and second most common genetic disorder, behind Down syndrome•Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in inf

  22. Slide 22: Rationale for Zygel in 22q

    U.S. & EU ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22qRationale for Zygel in 22qZynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 •Overlapping symptoms with FXS and ASD•Associated with increased anxiety, irritability, social withdrawal and social interaction problems •Ca

  23. Slide 23: INSPIRE Phase 2 Trial Design

    INSPIREPhase 2 Trial DesignZynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 Period 1: Completed 14 weeks 4 to 15 years oldWith 22q11.2 Deletion Syndrome Zygel(n = 20)250 mg daily (≤35kg)500 mg daily (>35kg)(weight-based dose)Period 2: Ongoing 24 weeks Efficacy assessments inclu

  24. Slide 24: INSPIRE Trial Results

    •Statistically significant improvements at 14 weeks of treatment compared to baseline for multiple efficacy assessments:•The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS)•All five subscales of the Aberrant Behavior Checklist –Community (ABC-C)•Pediatric Anxiety

  25. Slide 25: Significant Improvement in Anxiety as Measured by the PARS-R

    Efficacy: Significant Improvement in Anxiety as Measured by the PARS-RZynerba Pharmaceuticals | Advancing Science. Improving Connections. 25 Mean PARS-R Scores and Percentage ImprovementPARS-R, Pediatric Anxiety Rating Scale-Revised. 14.78.50246 8101214 1640.6%(P=.0005) ImprovementBaseline (n=15)Wee

  26. Slide 26: Significant Improvements in ADAMS and ABC-C Scores

    Efficacy: Significant Improvements in ADAMS Total and Subscale Scores and All ABC-C Subscale ScoresZynerba Pharmaceuticals | Advancing Science. Improving Connections. 26 ADAMS, Anxiety, Depression, and Mood Scale.45.3%(P=.0005)The efficacy analysis included 16 patients for ADAMS (1 patient did not h

  27. Slide 27: Next Steps in 22q

    Next Steps in 22qZynerba Pharmaceuticals | Advancing Science. Improving Connections. 27 Discuss regulatory pathway with FDA Initiate Phase 3 program after FDA discussions and RECONNECT toplineresultsNovember 2022

  28. Slide 28: Autism Spectrum Disorder

    Autism Spectrum Disorder

  29. Slide 29: Rationale for Zygel in Autism Spectrum Disorder (ASD)

    Rationale for Zygel in Autism Spectrum Disorder (ASD)Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 29 •Results from FXS trials suggested spectrum of activity against behaviors also seen in ASD: irritability, social avoidance and anxiety•Studies suggested ASD is linked to disrup

  30. Slide 30: BRIGHT Open-Label Phase 2 Trial Design

    BRIGHTOpen-label Phase 2 Trial DesignZynerba Pharmaceuticals | Advancing Science. Improving Connections. 30 Period 1 14 weeks 3 to 16 years oldModerate-to-Severe ASD Zygel(n = 37)250 mg daily (≤35kg)500 mg daily (>35kg)(weight-based dose)Period 2 24 weeks 18 Patientswith ≥ 35% improvementin Irritabi

  31. Slide 31: BRIGHT Phase 2 Trial Results: Period 1

    BRIGHTPhase 2 Trial Results: Period 1Statistically Significant Results at Week 14 Compared to Baseline (Completers in Efficacy Population n=28†)Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 31 †n=26 for ABC-C inappropriate speech; *Statistically significant; Full data available

  32. Slide 32: BRIGHT Period 2 Results: Improvements Sustained Through Week 38

    50%(P<0.0001)61%(P<0.0001)60%(P<0.0001)53%(P<0.0001)56%(P<0.0001) 0510 1520253035 40IrritabilityInappropriate SpeechStereotypySocial WithdrawalHyperactivityABC-C Subscale ScoreMean Scores Baseline Week 14 Week 38BRIGHT Period 2 Results: Statistically Significant Improvements from Baseline Sustained

  33. Slide 33: Next Steps in ASD

    Next Steps in ASDZynerba Pharmaceuticals | Advancing Science. Improving Connections. 33 Submit Investigational New Drug (IND) application specific to ASD with finalized clinical protocolASD is now third in priority and initiation of Phase 3 program is deferred at this timeNovember 2022

  34. Slide 34: Positioned for Success

    Positioned for Success

  35. Slide 35: Leadership

    LeadershipZynerba Pharmaceuticals | Advancing Science. Improving Connections. 35 Armando AnidoChairman of the Board and CEO Terri B. SebreePresident Jim FickenscherCFO and VP, Corporate Development Paul KirschVP, Regulatory Affairs and Quality Assurance Joe ApostolicoVP, Human Resources Terry HurstG

  36. Slide 36: Financial Strength

    Financial StrengthZynerba Pharmaceuticals | Advancing Science. Improving Connections. 36 CASH AND CASH EQUIVALENTS$55.9Mas of September 30, 2022;expected to be sufficient to fund operations and capital requirements into Q1 2024BALANCE SHEET CLEANNo debt, 47.1M shares outstanding (as of November 9, 2

  37. Slide 37: A Year of Clinical Progress Ahead

    A Year of Clinical Progress AheadZynerba Pharmaceuticals | Advancing Science. Improving Connections. 37 Fragile X Syndrome (FXS) Autism Spectrum Disorder (ASD) 22q Deletion Syndrome (22q) U.S. Orphan Drug and Fast Track designations; EU Orphan Drug designationU.S. and EU Orphan Drug designations Piv

  38. Slide 38: Zynerba Vision for Future Growth

    •Launch Zygel for FXS into a $1.9B+ U.S. market opportunity•Establish a fully integrated organization with U.S. commercial presence•Preparing for EU approval in FXS•Advance 22q and ASD Ph3 programs towards completion •Leader in transdermal cannabidiol delivery •Late-stage clinical company with multi

  39. Slide 39: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  40. Slide 40: Thank you!

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQZYNE Thank you!

Zynerba Pharmaceuticals — Investor Presentation (November 2022) on 6ix